Michaël Mingueneau

WORK HISTORY

EDUCATION

SKILLS

ABOUT MICHAËL MINGUENEAU

Research and drug discovery leader experienced with target identification/validation and successful advancement of programs from early preclinical stage towards R2D transition and IND/phase 1 in the fields of autoimmunity, neuroinflammation and immuno-oncology. Deep strategical, technological, and analytical expertise of cellular and molecular immunology and experienced with multiple drug discovery modalities (reversible and covalent small molecules, PROTAC protein degraders, antibody and RNA/LNP-based therapeutics, chimeric antigen receptor (CAR)-T). Strong knowledge, expertise and high-impact publication record in the fields of innate and adaptive immunology including T cell, B cell and myeloid cell biology in healthy and disease states. Established track record of building highly performing, collaborative and purpose-driven teams in different types of drug discovery organizations.Current responsibilities at SAIL Biomedicines include oversight of immunology research unit vision, strategy and team to transform the care of patients with immunological diseases with RNA programmable medicines by:• Leading SAIL’s lead program and cross-functional team (in vivo CAR-T cell program) towards Ph. 1 as Program Lead & Executive • Identifying and unlocking innovative therapeutic opportunities enabled by RNA-programmable medicines and designing differentiated drug candidates as Head of Immunology unit (12-15 team members).• Maximizing the potential of RNA programmable medicines for therapeutic applications by increasing our understanding of the immunoreactivity of RNA-based therapeutics.SKILLS AND QUALIFICATONS:• Strong project & people leadership experience in cross-functional and highly matrixed work settings with direct responsibility over small and larger teams of 10-20 scientists in current and prior roles; prior or current mentorship of PhD students and postdocs; R&D project lead of highly cross-functional teams. • Strong knowledge of small, large molecule, PROTAC target protein degraders, and RNA/LNP-based therapeutic drug discovery with proven track record of successful advancement of programs from early stage to R2D/IND and established understanding of the complexities and specificities of CNS drug discovery.• Robust academic visibility and publication track record